Goldman Sachs Maintains Neutral on Teva Pharmaceutical Indus, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Nathan Rich maintains a Neutral rating on Teva Pharmaceutical Industries (NYSE:TEVA) and raises the price target from $10 to $11.
February 05, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Teva Pharmaceutical Industries and raises the price target from $10 to $11.
The increase in price target by Goldman Sachs suggests a positive outlook on the stock's future performance, potentially leading to a short-term increase in stock price. However, the Neutral rating indicates that the stock might not outperform the market significantly.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90